Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1273.251
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1273.251 is a variant-specific mRNA vaccine developed by Moderna for the prevention of COVID-19. As part of the mRNA-1273 platform, it consists of a synthetic messenger RNA sequence encoding the SARS-CoV-2 spike (S) glycoprotein, stabilized in the prefusion conformation. The mRNA is encapsulated within lipid nanoparticles (LNPs) composed of SM-102, cholesterol, DSPC, and PEG2000-DMG to facilitate delivery into host cells. Once administered, the mRNA is translated by the host's cellular machinery to produce the spike protein, triggering an immune response. mRNA-1273.251 is specifically designed to target emerging SARS-CoV-2 variants and is being evaluated in clinical trials to assess its immunogenicity and safety as a booster in previously vaccinated individuals.
02
Targets
80S ribosome (Ribosome and ribosomal components)Innate immune RNA sensorsACE2 (Angiotensin-converting enzyme 2)Host cell plasma membrane lipidsBCR (B-cell receptor)BMP (Bone morphogenetic protein family)SARS-CoV-2 spikeTCR (T-cell receptor)
Beyond the preview
Go deeper on mRNA-1273.251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1273.251.